Designed to provide a quantitative assessment to support what a
surgeon must otherwise feel.
The Elora® Platform is intended to aid surgeons in identifying residual cancer after tumour removal, inside the patient, at the moment the decision is being made, with the goal of guiding the surgeon to remove all the cancer the first time.
.png)
.png)
“Ziva means light. It names exactly what we do: bring light to what a surgeon cannot otherwise see, in the moment it matters most.”
BUILT ON QME
Quantitative Micro-Elastography, developed over a decade of research at the University of Western Australia and the Harry Perkins Institute of Medical Research. The science is published; Ziva owns the technology built from it.
The Elora® Breast System.
WHAT TISSUE INTELLIGENCE™ MEANS
The Elora® Breast System is powered by Ziva’s QME technology – quantitative micro-elastography. QME is being developed to provide a quantitative read of the tissue itself: its stiffness, its microarchitecture, at a scale and resolution beyond the surgeon's sight or touch. Intended for use during the breast-conserving surgery procedure, while the choice is still live.
The System comprises three hardware components – a mobile workstation, a handheld probe and a disposable cap – run by Ziva’s proprietary QME software.
During breast-conserving surgery, Elora® is being designed to give surgeons real-time, high-resolution imaging of tissue as they operate, distinguishing diseased tissue from healthy tissue in the moment a decision is being made. Elora® is designed to integrate into the surgical workflow and to complement pathology rather than replace it. The goal is more patients moving forward after a single surgery, confident their cancer is behind them.
What Elora® Breast Does
.png)
“Ziva means light. It names exactly what we do: bring light to what a surgeon cannot otherwise see, in the moment it matters most.”
BUILT ON QME
Quantitative Micro-Elastography, developed over a decade of research at the University of Western Australia and the Harry Perkins Institute of Medical Research. The science is published; Ziva owns the technology built from it.
QME Technology
Cancerous breast tissue is around 4-6x stiffer than healthy breast tissue ³ ⁴. The Elora® Platform is built on QME, combining two established techniques: Optical Coherence Tomography, which uses light to produce a microscale view of tissue architecture, and micro-elastography, which measures the stiffness of that tissue. Because diseased tissue is measurably stiffer than healthy tissue, the two together let Elora® reveal the difference clearly and immediately.
Direct from
the cavity
Freedom from dyes/biological markers
Designed to fit seamlessly into surgical workflows
The Elora® Breast System is the first expression, not the limit.
What Ziva is striving to do today is focused in breast cancer: discerning diseased tissue from healthy tissue in real time, in the surgical cavity, complementary to pathology rather than a replacement for it. The same core capability and technology is built to extend further as each new use is proven through evidence.
The discernment to see what
a surgeon can't otherwise feel.
Ten years ago, a small team in Perth set out to solve one very specific problem: to give surgeons a way to see what they had, until then, only been able to feel. Ziva has grown into a Tissue Intelligence company with the intention to solve this very problem, and beyond.
Ziva’s QME technology — quantitative micro-elastography emerged from a decade of foundational research at UWA and the Harry Perkins Institute, and was translated into a surgical platform through OncoRes' proprietary engineering and development. An exclusive commercial license and 44 patent families protect the technology, the probe design and the system.
Sources
¹ Kim, Y., Ganduglia-Cazaban, C., Tamirisa, N., Lucci, A., & Krause, T. M. (2024). Contemporary Analysis of Reexcision and Conversion to Mastectomy Rates and Associated Healthcare Costs for Women Undergoing Breast-Conserving Surgery. Annals of surgical oncology, 1-12.
² Bundred JR, Michael S, Stuart B, Cutress RI, Beckmann K, Holleczek B, Dahlstrom JE, Gath J, Dodwell D, Bundred NJ. Margin status and survival outcomes after breast cancer conservation surgery: prospectively registered systematic review and meta-analysis. BMJ. 2022 Sep 21;378:e070346. doi: 10.1136/bmj-2022-070346. PMID: 36130770; PMCID: PMC9490551
³ Sayed, A., Layne, G., Abraham, J., & Mukdadi, O. (2013). Nonlinear characterization of breast cancer using multi-compression 3D ultrasound elastography in vivo. Ultrasonics, 53(5), 979–991. https://doi.org/10.1016/j.ultras.2013.01.005
⁴ Srivastava, A., Verma, Y., Rao, K. D., & Gupta, P. K. (2011). Determination of elastic properties of resected human breast tissue samples using optical coherence tomographic elastography. Strain, 47(1), 75–87. https://doi.org/10.1111/j.1475-1305.2009.00627.x